EGFR and non-small cell lung carcinoma: Compared with the EGFR-TKIs mono therapy, TKIs combined angiogenesis inhibitors therapy can prolonged the PFS of advanced EGFR-mutant NSCLC with statistical significance [HR:0.65 (95%CI: 0.59~0.73, P<0.00001)] (Fig. 3).